Journal of Microbiology and Biotechnology

  • 제32권1호
  • /
  • Pages.126-140
  • /
  • 2022
  • /
  • 1017-7825(pISSN)
  • /
  • 1738-8872(eISSN)
한국미생물·생명공학회 (The Korean Society for Microbiology and Biotechnology)
권호 표지
DOI QR코드

DOI QR Code

Global Proteomic Analysis of Mesenchymal Stem Cells Derived from Human Embryonic Stem Cells via Connective Tissue Growth Factor Treatment under Chemically Defined Feeder-Free Culture Conditions

  • Seo, Ji-Hye (Department of Dental Pharmacology, School of Dentistry, Jeonbuk National University) ;
  • Jeon, Young-Joo (Stem Cell Convergence Research Center, Korea Research Institute of Bioscience and Biotechnology (KRIBB))
  • 투고 : 2021.10.21
  • 심사 : 2021.11.04
  • 발행 : 2022.01.28
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Stem cells can be applied usefully in basic research and clinical field due to their differentiation and self-renewal capacity. The aim of this study was to establish an effective novel therapeutic cellular source and create its molecular expression profile map to elucidate the possible therapeutic mechanism and signaling pathway. We successfully obtained a mesenchymal stem cell population from human embryonic stem cells (hESCs) cultured on chemically defined feeder-free conditions and treated with connective tissue growth factor (CTGF) and performed the expressive proteomic approach to elucidate the molecular basis. We further selected 12 differentially expressed proteins in CTGF-induced hESC-derived mesenchymal stem cells (C-hESC-MSCs), which were found to be involved in the metabolic process, immune response, cell signaling, and cell proliferation, as compared to bone marrow derived-MSCs(BM-MSCs). Moreover, these up-regulated proteins were potentially related to the Wnt/β-catenin pathway. These results suggest that C-hESC-MSCs are a highly proliferative cell population, which can interact with the Wnt/β-catenin signaling pathway; thus, due to the upregulated cell survival ability or downregulated apoptosis effects of C-hESC-MSCs, these can be used as an unlimited cellular source in the cell therapy field for a higher therapeutic potential. Overall, the study provided valuable insights into the molecular functioning of hESC derivatives as a valuable cellular source.

키워드

과제정보

This research was supported by the Korea Research Institute of Bioscience and Biotechnology (KRIBB) Research Initiative Program (KGM5362111) and the National Research Foundation of Korea (NRF) funded by the Ministry of Education (NRF-2021R1I1A1A01048981).

참고문헌

  1. Thomson JA, Itskovitz-Eldor J, Shapiro SS, Waknitz MA, Swiergiel JJ, Marshall VS, et al. 1998. Embryonic stem cell lines derived from human blastocysts. Science 282: 1145-1147. https://doi.org/10.1126/science.282.5391.1145
  2. Kim J, Moon SH, Lee SH, Lee DR, Koh GY, Chung HM. 2007. Effective isolation and culture of endothelial cells in embryoid body differentiated from human embryonic stem cells. Stem Cells Dev. 16: 269-280. https://doi.org/10.1089/scd.2006.0108
  3. Chae JI, Kim J, Son MY, Jeon YJ, Kim DW, Kim HE, et al. 2013. Cardioprotective molecules are enriched in beating cardiomyocytes derived from human embryonic stem cells. Int. J. Cardiol. 165: 341-354. https://doi.org/10.1016/j.ijcard.2012.07.013
  4. Volarevic V, Markovic BS, Gazdic M, Volarevic A, Jovicic N, Arsenijevic N, et al. 2018. Ethical and safety issues of stem cell-based therapy. Int. J. Med. Sci. 15: 36-45. https://doi.org/10.7150/ijms.21666
  5. Kim J, Shin JM, Jeon YJ, Chung HM, Chae JI. 2012. Proteomic validation of multifunctional molecules in mesenchymal stem cells derived from human bone marrow, umbilical cord blood and peripheral blood. PLoS One 7: e32350. https://doi.org/10.1371/journal.pone.0032350
  6. Luft FC. 2008. CCN2, the connective tissue growth factor. J. Mol. Med. (Berl) 86: 1-3. https://doi.org/10.1007/s00109-007-0287-x
  7. Chu CY, Chang CC, Prakash E, Kuo ML. 2008. Connective tissue growth factor (CTGF) and cancer progression. J. Biomed. Sci. 15: 675-685. https://doi.org/10.1007/s11373-008-9264-9
  8. Chang CC, Hsu WH, Wang CC, Chou CH, Kuo MY, Lin BR, et al. 2013. Connective tissue growth factor activates pluripotency genes and mesenchymal-epithelial transition in head and neck cancer cells. Cancer Res. 73: 4147-4157. https://doi.org/10.1158/0008-5472.CAN-12-4085
  9. Chang CC, Shih JY, Jeng YM, Su JL, Lin BZ, Chen ST, et al. 2004. Connective tissue growth factor and its role in lung adenocarcinoma invasion and metastasis. J. Natl. Cancer Inst. 96: 364-375. https://doi.org/10.1093/jnci/djh059
  10. Mullis TC, Tang X, Chong KT. 2008. Expression of connective tissue growth factor (CTGF/CCN2) in head and neck squamous cell carcinoma. J. Clin. Pathol. 61: 606-610. https://doi.org/10.1136/jcp.2007.052795
  11. Hiyama A, Morita K, Sakai D, Watanabe M. 2018. CCN family member 2/connective tissue growth factor (CCN2/CTGF) is regulated by Wnt-beta-catenin signaling in nucleus pulposus cells. Arthritis Res. Ther. 20: 217. https://doi.org/10.1186/s13075-018-1723-8
  12. Chen PS, Wang MY, Wu SN, Su JL, Hong CC, Chuang SE, et al. 2007. CTGF enhances the motility of breast cancer cells via an integrin-alphavbeta3-ERK1/2-dependent S100A4-upregulated pathway. J. Cell Sci. 120: 2053-2065. https://doi.org/10.1242/jcs.03460
  13. Yang Z, Sun L, Nie H, Liu H, Liu G, Guan G. 2015. Connective tissue growth factor induces tubular epithelial to mesenchymal transition through the activation of canonical Wnt signaling in vitro. Ren. Fail. 37: 129-135. https://doi.org/10.3109/0886022X.2014.967699
  14. Rooney B, O'Donovan H, Gaffney A, Browne M, Faherty N, Curran SP, et al. 2011. CTGF/CCN2 activates canonical Wnt signalling in mesangial cells through LRP6: implications for the pathogenesis of diabetic nephropathy. FEBS Lett. 585: 531-538. https://doi.org/10.1016/j.febslet.2011.01.004
  15. Niehrs C. 2012. The complex world of WNT receptor signalling. Nat. Rev. Mol. Cell Biol. 13: 767-779. https://doi.org/10.1038/nrm3470
  16. Pandur P, Maurus D, Kuhl M. 2002. Increasingly complex: new players enter the Wnt signaling network. Bioessays 24: 881-884. https://doi.org/10.1002/bies.10164
  17. James AW. 2013. Review of signaling pathways governing MSC osteogenic and adipogenic differentiation. Scientifica (Cairo) 2013: 684736. https://doi.org/10.1155/2013/684736
  18. Soon-Jung Park Y-JJ, Jumi Kim, Jeong-Min Shin, Jung-Il Chae, Hyung-Min Chung. 2010. Derivation of MSC like-cell population from feeder free cultured hESC and their proteomic analysis for comparison study with BM-MSC. Reprod. Dev. Biol 34: 143-151.
  19. Varghese S, Braggio DA, Gillespie J, Toland AE, Pollock R, Mayerson J, et al. 2017. TGF-beta and CTGF are mitogenic output mediators of Wnt/beta-catenin signaling in desmoid fibromatosis. Appl. Immunohistochem. Mol. Morphol. 25: 559-565. https://doi.org/10.1097/pai.0000000000000340
  20. Shin JM, Kim J, Kim HE, Lee MJ, Lee KI, Yoo EG, et al. 2011. Enhancement of differentiation efficiency of hESCs into vascular lineage cells in hypoxia via a paracrine mechanism. Stem Cell Res. 7: 173-185. https://doi.org/10.1016/j.scr.2011.06.002
  21. Garcia P, Leal P, Ili C, Brebi P, Alvarez H, Roa JC. 2013. Inhibition of connective tissue growth factor (CTGF/CCN2) in gallbladder cancer cells leads to decreased growth in vitro. Int. J. Exp. Pathol. 94: 195-202. https://doi.org/10.1111/iep.12023
  22. Zhang Z, Zheng F, Yu Z, Hao J, Chen M, Yu W, et al. 2017. XRCC5 cooperates with p300 to promote cyclooxygenase-2 expression and tumor growth in colon cancers. PLoS One 12: e0186900. https://doi.org/10.1371/journal.pone.0186900
  23. Ghosh G, Li G, Myung K, Hendrickson EA. 2007. The lethality of Ku86 (XRCC5) loss-of-function mutations in human cells is independent of p53 (TP53). Radiat. Res. 167: 66-79. https://doi.org/10.1667/rr0692.1
  24. Jin S, Inoue S, Weaver DT. 1998. Differential etoposide sensitivity of cells deficient in the Ku and DNA-PKcs components of the DNA-dependent protein kinase. Carcinogenesis 19: 965-971. https://doi.org/10.1093/carcin/19.6.965
  25. Mahaira LG, Katsara O, Pappou E, Iliopoulou EG, Fortis S, Antsaklis A, et al. 2014. IGF2BP1 expression in human mesenchymal stem cells significantly affects their proliferation and is under the epigenetic control of TET1/2 demethylases. Stem Cells Dev. 23: 2501-2512. https://doi.org/10.1089/scd.2013.0604
  26. Elcheva IA, Wood T, Chiarolanzio K, Chim B, Wong M, Singh V, et al. 2020. RNA-binding protein IGF2BP1 maintains leukemia stem cell properties by regulating HOXB4, MYB, and ALDH1A1. Leukemia 34: 1354-1363. https://doi.org/10.1038/s41375-019-0656-9
  27. Zhang J, Luo W, Chi X, Zhang L, Ren Q, Wang H, et al. 2020. IGF2BP1 silencing inhibits proliferation and induces apoptosis of high glucose-induced non-small cell lung cancer cells by regulating Netrin-1. Arch. Biochem. Biophys. 693: 108581. https://doi.org/10.1016/j.abb.2020.108581
  28. Cao X, Li F, Shao J, Lv J, Chang A, Dong W, et al. 2021. Circular RNA hsa_circ_0102231 sponges miR-145 to promote non-small cell lung cancer cell proliferation by up-regulating the expression of RBBP4. J. Biochem. 169: 65-73. https://doi.org/10.1093/jb/mvaa093
  29. Miao X, Sun T, Barletta H, Mager J, Cui W. 2020. Loss of RBBP4 results in defective inner cell mass, severe apoptosis, hyperacetylated histones and preimplantation lethality in micedagger. Biol. Reprod. 103: 13-23. https://doi.org/10.1093/biolre/ioaa046
  30. Li YD, Lv Z, Zhu WF. 2020. RBBP4 promotes colon cancer malignant progression via regulating Wnt/beta-catenin pathway. World J. Gastroenterol. 26: 5328-5342. https://doi.org/10.3748/wjg.v26.i35.5328
  31. Essers J, Theil AF, Baldeyron C, van Cappellen WA, Houtsmuller AB, Kanaar R, et al. 2005. Nuclear dynamics of PCNA in DNA replication and repair. Mol. Cell Biol. 25: 9350-9359. https://doi.org/10.1128/MCB.25.21.9350-9359.2005
  32. Dietrich DR. 1993. Toxicological and pathological applications of proliferating cell nuclear antigen (PCNA), a novel endogenous marker for cell proliferation. Crit. Rev. Toxicol. 23: 77-109. https://doi.org/10.3109/10408449309104075
  33. Lim MJ, Wang XW. 2006. Nucleophosmin and human cancer. Cancer Detect. Prev. 30: 481-490. https://doi.org/10.1016/j.cdp.2006.10.008
  34. Cela I, Di Matteo A, Federici L. 2020. Nucleophosmin in its interaction with ligands. Int. J. Mol. Sci. 21: 4885. https://doi.org/10.3390/ijms21144885
  35. Brodska B, Sasinkova M, Kuzelova K. 2019. Nucleophosmin in leukemia: Consequences of anchor loss. Int. J. Biochem. Cell Biol. 111: 52-62. https://doi.org/10.1016/j.biocel.2019.04.007
  36. Box JK, Paquet N, Adams MN, Boucher D, Bolderson E, O'Byrne KJ, et al. 2016. Nucleophosmin: from structure and function to disease development. BMC Mol. Biol. 17: 19. https://doi.org/10.1186/s12867-016-0073-9
  37. Shinohara H, Udagawa J, Morishita R, Ueda H, Otani H, Semba R, et al. 2004. Gi2 signaling enhances proliferation of neural progenitor cells in the developing brain. J. Biol. Chem. 279: 41141-41148. https://doi.org/10.1074/jbc.M406721200
  38. Dhanasekaran N, Tsim ST, Dermott JM, Onesime D. 1998. Regulation of cell proliferation by G proteins. Oncogene 17: 1383-1394. https://doi.org/10.1038/sj/onc/1202242
  39. Peters DG, Kudla DM, Deloia JA, Chu TJ, Fairfull L, Edwards RP, et al. 2005. Comparative gene expression analysis of ovarian carcinoma and normal ovarian epithelium by serial analysis of gene expression. Cancer Epidemiol. Biomarkers Prev. 14: 1717-1723. https://doi.org/10.1158/1055-9965.EPI-04-0704
  40. Fu X, Li Y, Alvero A, Li J, Wu Q, Xiao Q, et al. 2016. MicroRNA-222-3p/GNAI2/AKT axis inhibits epithelial ovarian cancer cell growth and associates with good overall survival. Oncotarget 7: 80633-80654. https://doi.org/10.18632/oncotarget.13017
  41. Jiang L, Dai Y, Liu X, Wang C, Wang A, Chen Z, et al. 2011. Identification and experimental validation of G protein alpha inhibiting activity polypeptide 2 (GNAI2) as a microRNA-138 target in tongue squamous cell carcinoma. Hum. Genet. 129: 189-197. https://doi.org/10.1007/s00439-010-0915-3
  42. Murray P, Edgar D. 2000. Regulation of programmed cell death by basement membranes in embryonic development. J. Cell Biol. 150: 1215-1221. https://doi.org/10.1083/jcb.150.5.1215
  43. Hassani F, Oryan S, Eftekhari-Yazdi P, Bazrgar M, Moini A, Nasiri N, et al. 2019. Downregulation of extracellular matrix and cell adhesion molecules in cumulus cells of infertile polycystic ovary syndrome women with and without insulin resistance. Cell J. 21: 35-42.
  44. Ozegowska K, Brazert M, Ciesiolka S, Nawrocki MJ, Kranc W, Celichowski P, et al. 2019. Genes involved in the processes of cell proliferation, migration, adhesion, and tissue development as new potential markers of porcine granulosa cellular processes in vitro: a microarray approach. DNA Cell Biol. 38: 549-560. https://doi.org/10.1089/dna.2018.4467
  45. Zhang Y, Xi S, Chen J, Zhou D, Gao H, Zhou Z, et al. 2017. Overexpression of LAMC1 predicts poor prognosis and enhances tumor cell invasion and migration in hepatocellular carcinoma. J. Cancer 8: 2992-3000. https://doi.org/10.7150/jca.21038
  46. Ye G, Qin Y, Wang S, Pan D, Xu S, Wu C, et al. 2019. Lamc1 promotes the Warburg effect in hepatocellular carcinoma cells by regulating PKM2 expression through AKT pathway. Cancer Biol. Ther. 20: 711-719. https://doi.org/10.1080/15384047.2018.1564558
  47. Coates PJ, Nenutil R, McGregor A, Picksley SM, Crouch DH, Hall PA, et al. 2001. Mammalian prohibitin proteins respond to mitochondrial stress and decrease during cellular senescence. Exp. Cell Res. 265: 262-273. https://doi.org/10.1006/excr.2001.5166
  48. Yoshinaka T, Kosako H, Yoshizumi T, Furukawa R, Hirano Y, Kuge O, et al. 2019. Structural basis of mitochondrial scaffolds by prohibitin complexes: Insight into a role of the coiled-coil region. iScience 19: 1065-1078. https://doi.org/10.1016/j.isci.2019.08.056
  49. Zhou Z, Ai H, Li K, Yao X, Zhu W, Liu L, et al. 2018. Prohibitin 2 localizes in nucleolus to regulate ribosomal RNA transcription and facilitate cell proliferation in RD cells. Sci. Rep. 8: 1479. https://doi.org/10.1038/s41598-018-19917-7
  50. Sievers C, Billig G, Gottschalk K, Rudel T. 2010. Prohibitins are required for cancer cell proliferation and adhesion. PLoS One 5: e12735. https://doi.org/10.1371/journal.pone.0012735
  51. Kowno M, Watanabe-Susaki K, Ishimine H, Komazaki S, Enomoto K, Seki Y, et al. 2014. Prohibitin 2 regulates the proliferation and lineage-specific differentiation of mouse embryonic stem cells in mitochondria. PLoS One 9: e81552. https://doi.org/10.1371/journal.pone.0081552
  52. Zhou T, Li Y, Yang L, Liu L, Ju Y, Li C. 2017. Silencing of ANXA3 expression by RNA interference inhibits the proliferation and invasion of breast cancer cells. Oncol. Rep. 37: 388-398. https://doi.org/10.3892/or.2016.5251
  53. Branishte T, Arsenescu-Georgescu C, Tomescu MC, Braniste A, Mitu F. 2013. Annexins, calcium-dependent phospholipid binding proteins in irreducible heart failure. Rev. Med. Chir. Soc. Med. Nat. Iasi. 117: 648-653.
  54. Xie YQ, Fu D, He ZH, Tan QD. 2013. Prognostic value of Annexin A3 in human colorectal cancer and its correlation with hypoxia-inducible factor-1alpha. Oncol. Lett. 6: 1631-1635. https://doi.org/10.3892/ol.2013.1620
  55. Wang L, Wu H, Wang L, Zhang H, Lu J, Liang Z, et al. 2017. Asporin promotes pancreatic cancer cell invasion and migration by regulating the epithelial-to-mesenchymal transition (EMT) through both autocrine and paracrine mechanisms. Cancer Lett. 398: 24-36. https://doi.org/10.1016/j.canlet.2017.04.001
  56. Roessler M, Rollinger W, Mantovani-Endl L, Hagmann ML, Palme S, Berndt P, et al. 2006. Identification of PSME3 as a novel serum tumor marker for colorectal cancer by combining two-dimensional polyacrylamide gel electrophoresis with a strictly mass spectrometry-based approach for data analysis. Mol. Cell. Proteomics 5: 2092-2101. https://doi.org/10.1074/mcp.M600118-MCP200
  57. VIJAY Kumar KALASKAR NDT, Aman George, Tiziana Cogliati and Brian Patrick Brooks. 2019. Mutations in proteasome 26S subunit, non-ATPase 5 gene (psmd5) cause ocular coloboma and vertebral defects. ARVO Annual Meeting Abstract.
  58. Kaneko T, Hamazaki J, Iemura S, Sasaki K, Furuyama K, Natsume T, et al. 2009. Assembly pathway of the Mammalian proteasome base subcomplex is mediated by multiple specific chaperones. Cell 137: 914-925. https://doi.org/10.1016/j.cell.2009.05.008
  59. Luo Q, Kang Q, Si W, Jiang W, Park JK, Peng Y, et al. 2004. Connective tissue growth factor (CTGF) is regulated by Wnt and bone morphogenetic proteins signaling in osteoblast differentiation of mesenchymal stem cells. J. Biol. Chem. 279: 55958-55968. https://doi.org/10.1074/jbc.M407810200
  60. Shaw J, Kirshenbaum LA. 2006. Prime time for JNK-mediated Akt reactivation in hypoxia-reoxygenation. Circ. Res. 98: 7-9. https://doi.org/10.1161/01.RES.0000200397.22663.b6
  61. Zhang W, Liu HT. 2002. MAPK signal pathways in the regulation of cell proliferation in mammalian cells. Cell Res. 12: 9-18. https://doi.org/10.1038/sj.cr.7290105
  62. Johnson GL, Lapadat R. 2002. Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science 298: 1911-1912. https://doi.org/10.1126/science.1072682
  63. Zhang L, Zhang Y, Wu Y, Yu J, Zhang Y, Zeng F, et al. 2019. Role of the balance of Akt and MAPK pathways in the exercise-regulated phenotype switching in spontaneously hypertensive rats. Int. J. Mol. Sci. 20: 5690. https://doi.org/10.3390/ijms20225690
  64. Bubici C, Papa S. 2014. JNK signalling in cancer: in need of new, smarter therapeutic targets. Br. J. Pharmacol. 171: 24-37. https://doi.org/10.1111/bph.12432
  65. Davies C, Tournier C. 2012. Exploring the function of the JNK (c-Jun N-terminal kinase) signalling pathway in physiological and pathological processes to design novel therapeutic strategies. Biochem. Soc. Trans. 40: 85-89. https://doi.org/10.1042/BST20110641
  66. Coulthard LR, White DE, Jones DL, McDermott MF, Burchill SA. 2009. p38(MAPK): stress responses from molecular mechanisms to therapeutics. Trends Mol. Med. 15: 369-379. https://doi.org/10.1016/j.molmed.2009.06.005